MECLIZINE HYDROCHLORIDE- meclizine hydrochloride tablet
REMEDYREPACK INC.
----------
Meclizine Hydrochloride Tablets USP, 12.5 mg and 25 mg
Rx Only
DESCRIPTION
Chemically, meclizine hydrochloride is 1-( p-chloro-α-phenylbenzyl)-4-( m-methylbenzyl) piperazine dihydrochloride monohydrate.
C 25H 27CIN 2·2HCl·H 20 M.W. 481.89
Meclizine hydrochloride tablets, USP are available in two different strengths, 12.5 mg and 25 mg. Inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. The 12.5 mg tablet also contains FD&C Blue #1 Aluminum Lake.
CLINICAL PHARMACOLOGY
Meclizine hydrochloride is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.
Pharmacokinetics
The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature.
Absorption
Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median T max value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.
Metabolism
The metabolic fate of meclizine in humans is unknown. In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP 2D6 was found to be the dominant enzyme for metabolism of meclizine.
The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.
INDICATIONS AND USAGE
Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system.
CONTRAINDICATIONS
Meclizine hydrochloride tablets are contraindicated in individuals who have shown a previous hypersensitivity to it.
WARNINGS
Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.
Patients should avoid alcoholic beverages while taking this drug.
Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.
PRECAUTIONS
Pediatric Use
Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.
Pregnancy
Pregnancy Category B.
Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when meclizine is administered to a nursing woman.
Hepatic Impairment
The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine undergoes metabolism, hepatic impairment may result in increased systemic exposure of the drug. Treatment with meclizine should be administered with caution in patients with hepatic impairment.
Renal Impairment
The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Due to a potential drug/metabolite accumulation, meclizine should be administered with caution in patients with renal impairment and in the elderly as renal function generally declines with age.
Drug Interactions
There may be increased CNS depression when meclizine is administered concurrently with other CNS depressants, including alcohol, tranquilizers, and sedatives. (see WARNINGS)
Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore there is a possibility for a drug interaction between meclizine and CYP2D6 inhibitors.
ADVERSE REACTIONS
Anaphylactoid reaction, drowsiness, dry mouth, headache, fatigue, vomiting and, on rare occasions, blurred vision have been reported.
To report SUSPECTED ADVERSE REACTIONS, contact Epic Pharma, LLC at
1-888-374-2791 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
HOW SUPPLIED
Meclizine Hydrochloride Tablets, USP are available as follows:
12.5 mg, blue, modified oval-shaped tablets, de-bossed “ Є12” on one side and plain on the other side. They are supplied as follows:
NDC 42806-012-01 in bottles of 100
NDC 42806-012-10 in bottles of 1000
25 mg, white, modified oval-shaped tablets, de-bossed “ Є14” on one side and plain on the other side. They are supplied as follows:
NDC 42806-014-01 in bottles of 100
NDC 42806-014-10 in bottles of 1000
Store at 20º to 25ºC (68 to 77ºF) [See USP Controlled Room Temperature]. Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required.
Manufactured by:
Epic Pharma, LLC
Laurelton, NY 11413
Rev.05-2018-00
MF012REV05/18
OE1035
PRINCIPAL DISPLAY PANEL
DRUG: Meclizine Hydrochloride
GENERIC: Meclizine Hydrochloride
DOSAGE: TABLET
ADMINSTRATION: ORAL
NDC: 70518-0421-0
NDC: 70518-0421-1
COLOR: blue
SHAPE: OVAL
SCORE: No score
SIZE: 10 mm
IMPRINT: E12
PACKAGING: 90 in 1 BOTTLE, PLASTIC
PACKAGING: 30 in 1 BOTTLE PLASTIC
ACTIVE INGREDIENT(S):
- MECLIZINE HYDROCHLORIDE 12.5mg in 1
INACTIVE INGREDIENT(S):
- CROSCARMELLOSE SODIUM
- MAGNESIUM STEARATE
- FD&C BLUE NO. 1
- CELLULOSE, MICROCRYSTALLINE
- LACTOSE MONOHYDRATE
| MECLIZINE HYDROCHLORIDE
meclizine hydrochloride tablet |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| Labeler - REMEDYREPACK INC. (829572556) |